{"title":"Improving Leukoplakia Follow-Up: Information Leaflets, Habit Cessation Counseling.","authors":"Shaila Mulki, Seema Mavinapalla, Supriya Hulimane, Elizabeth Sojan, Deviprasad Nooji, Vidya Gowdappa Doddawad","doi":"10.46883/2025.25921051","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The rising incidence of oral cancer necessitates widespread implementation of preventive measures, particularly in resource-challenged settings where visual examination and patient education are more feasible. Addressing the reluctance of patients clinically diagnosed with leukoplakia and reinforcing the importance of follow-up care is imperative. The study aims to assess the impact of patient information leaflets (PILs) and habit cessation counseling (HCC) on clinically diagnosed patients with leukoplakia.</p><p><strong>Materials and methods: </strong>The study included 60 clinically diagnosed cases of leukoplakia and was divided into 3 groups (20 participants each). Group 1 received an expert-designed PIL, group 2 had HCC, and group 3 received both PILs and HCC. All groups underwent follow-up assessments, including lesion reexamination and a structured questionnaire.</p><p><strong>Results: </strong>Group 3 demonstrated the highest level of understanding and application of the information, as reflected in both their attitude and practice toward their habits, and group 2 did better than group 1.</p><p><strong>Conclusion: </strong>The combination of a PIL and an HCC can effectively support reluctant patients with leukoplakia, fostering habit cessation and promoting lifestyle modifications through increased awareness.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 8","pages":"344-349"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology-New York","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46883/2025.25921051","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The rising incidence of oral cancer necessitates widespread implementation of preventive measures, particularly in resource-challenged settings where visual examination and patient education are more feasible. Addressing the reluctance of patients clinically diagnosed with leukoplakia and reinforcing the importance of follow-up care is imperative. The study aims to assess the impact of patient information leaflets (PILs) and habit cessation counseling (HCC) on clinically diagnosed patients with leukoplakia.
Materials and methods: The study included 60 clinically diagnosed cases of leukoplakia and was divided into 3 groups (20 participants each). Group 1 received an expert-designed PIL, group 2 had HCC, and group 3 received both PILs and HCC. All groups underwent follow-up assessments, including lesion reexamination and a structured questionnaire.
Results: Group 3 demonstrated the highest level of understanding and application of the information, as reflected in both their attitude and practice toward their habits, and group 2 did better than group 1.
Conclusion: The combination of a PIL and an HCC can effectively support reluctant patients with leukoplakia, fostering habit cessation and promoting lifestyle modifications through increased awareness.
期刊介绍:
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.